<div id="readability-page-1"><p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price traded up 9% during mid-day trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $21.46 and last traded at $21.6620. 878,698 shares were traded  during mid-day trading, a decline of 15% from the average session volume of 1,028,993 shares. The stock had previously closed at $19.88.</p><ul><li>From laggards to leaders: Small caps on the rise</li></ul><p>The company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The business had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same quarter last year, the company posted ($1.00) EPS. Arcus Biosciences's revenue for the quarter was down 45.8% on a year-over-year basis. </p><div><p><span></span><span>Get <strong>Arcus Biosciences</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>Several analysts recently commented on the company. Truist Financial  reaffirmed a &#34;buy&#34; rating and issued a $39.00 price target (up previously from $32.00) on shares of Arcus Biosciences in a research note on Tuesday, October 7th. Wall Street Zen upgraded Arcus Biosciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 9th. HC Wainwright boosted their target price on Arcus Biosciences from $24.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday. Wells Fargo &amp; Company boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, October 20th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $27.67.</p><ul><li>MarketBeat Week in Review – 7/10 - 7/14</li></ul><p><b>View Our Latest Stock Report on Arcus Biosciences</b></p><h2>Insider Buying and Selling at Arcus Biosciences</h2><p>In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 5,000 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the chief financial officer directly owned 92,138 shares of the company's stock, valued at $1,842,760. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Jennifer Jarrett sold 37,792 shares of the business's stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $15.05, for a total transaction of $568,769.60. Following the transaction, the chief operating officer directly owned 214,232 shares in the company, valued at approximately $3,224,191.60. The trade was a 15.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,702 shares of company stock valued at $906,081 over the last ninety days. Corporate insiders own  9.60% of the company's stock. </p><h2>Hedge Funds Weigh In On Arcus Biosciences</h2><ul><li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li></ul><p>Several large investors have recently made changes to their positions in the business. Amalgamated Bank boosted its position in shares of  Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company's stock valued at $266,000 after purchasing an additional 736 shares in the last quarter.  Nordea Investment Management AB boosted its position in shares of  Arcus Biosciences by 2.7% during the 3rd quarter. Nordea Investment Management AB now owns 328,459 shares of the company's stock valued at $4,332,000 after purchasing an additional 8,560 shares in the last quarter.  SG Americas Securities LLC boosted its position in shares of  Arcus Biosciences by 19.8% during the 3rd quarter. SG Americas Securities LLC now owns 32,774 shares of the company's stock valued at $446,000 after purchasing an additional 5,412 shares in the last quarter.  GAMMA Investing LLC boosted its position in shares of  Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter.  Finally, Corient Private Wealth LLC purchased a new stake in  Arcus Biosciences during the second quarter valued at about $180,000. Institutional investors own  92.89% of the company's stock. </p><h2>Arcus Biosciences Stock Up 9.0%</h2><p>The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.31 billion, a PE ratio of -6.83 and a beta of 0.77. The business's 50 day simple moving average is $13.37 and its 200 day simple moving average is $10.50. </p><h2>About Arcus Biosciences</h2> (Get Free Report)<p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Arcus Biosciences</li><li>Ride Out The Recession With These Dividend Kings </li><li>Forget AI: Amazon's Robots Could Be Coming for Your Job</li><li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li><li>Wayfair: A Way Good Stock to Buy and Hold for 2026</li><li>Insider Trading - What You Need to Know</li><li>Ford's Guidance Cut Couldn't Stop a New 52-Week High</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2><p>Before you consider Arcus Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RCUS

<p>Arcus Biosciences (NYSE:RCUS) shares rose 9% following a better-than-expected earnings report, trading at $21.66. The company reported earnings per share of ($1.27), surpassing estimates of ($1.33), with revenue of $26 million, exceeding the $19.89 million forecast. Analysts have set a consensus target price of $27.67, with seven rating it a Buy. Insider selling was noted, with CFO Robert C. Goeltz II selling 5,000 shares. Institutional investors hold 92.89% of the stock, reflecting strong interest in the company.</p>

Arcus Biosciences (NYSE:RCUS) Trading Up 9% on Better-Than-Expected Earnings